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Abstract
Objective: This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign 
gynecological disorders.
Material and methods: Sera were obtained from Chinese women prior to surgery for a  pelvic  mass  and  HE4  and  CA125 
levels  were  determined.  The  proportions  of  patients with HE4 and CA125 levels were compared.
Results: There were 68 Chinese women with benign diseases. HE4 levels were less elevated  than  CA125  (1%  V.S.  29%, 
P<0.001).  The  significant  difference  was observed  in  patients  with  endometriosis/endometriomas   in  which  HE4 
was  not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with 
cystadenoma  (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001).
Conclusion: HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.
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Introduction
Ovarian cancer was a leading cause of  gynecological 
cancer-related death in women, but most ovarian can-
cers were unfortunately diagnosed at an advanced stage 
when the survival rate was <20% despite aggressive 
surgery and chemotherapy.  A significant factor  con-
tributing  to  the  high  mortality  of   ovarian  cancer 
was  the  relatively a symptomatic progression of  this 
disease through the early stages1-3. Because cures were 
rare at advanced clinical stages, it was very important 
for placing emphasis on early  detection  to  reduce 
ovarian  cancer  mortality.  The  most  frequently  uti-
lized screening  modalities  include  pelvic  examina-
tions,   transvaginal   ultrasounds,   and cancer antigen 
125 (CA125) serum marker levels4.
CA125, a glycoprotein,  was detected from epithelial 
ovarian carcinoma antigen by Bast  in 1983.  CA125 
was  a high-molecular-weight  mucin  that  was enzy-
matically cleaved and shed from the surface of  ovarian 
cancer cells. The gene for CA125 was cloned in 2001 
and called MUC16 because of  the similarities between 
its product and the mucin family of  proteins. CA125 
was a large transmembrane glycoprotein with a carboxyl 
terminus, which included a cytoplasmic tail, a phospho-
rylation site for proteolytic  cleavage,  and  the  trans-
membrane  domain.  
The  biological  functions  of  CA125 were complex 
but seem to enhance the malignant potential of  ovar-
ian cancer cells.   CA125   played   an   important   role 
in   cellular   adhesion,   invasion,   and intraperito-
neal metastasis. Many studies had shown that CA125 
exists in the serum of  patients  with  epithelial  ovar-
ian  cancer.  Only  a  few  normal  tissues  expressed 
low levels   of   CA125   including   the  endometrium, 
fallopian   tube   epithelium,   lung parenchyma,  and 
cornea.  Significant  levels  of  CA125  were found in 
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some  benign ovarian tumors. CA125, which was mainly 
used for the diagnosis of  ovarian cancer, but also for 
the operation excision, the index of  curative effect ob-
servation after chemotherapy.  Although  CA125  was 
the  most  widely  used  biomarker  in  ovarian cancer, 
the sensitivity and specificity of  CA125 were far from 
ideal as its levels were elevated in approximately 80% of  
ovarian cancers4-8. Human epididymis secretory protein 
4 (HE4) was first identified in the epithelium of  the 
distal epididymis using Northern blot analysis and in 
situ transcript hybridization, which was referred to as 
WFDC2 because it contained two whey acidic protein 
(WAP) domains  and  a  four-disulphide  core  compris-
ing  eight  cysteine  residues.  HE4  was found to be 
over expressed in ovarian cancer, whereas its expression 
in normal tissues was low. It has been used for the early 
screening and differential diagnosis of  ovarian cancer, 
as well as for monitoring disease recurrence and pro-
gression. Several studies showed that HE4 had better 
sensitivity  and specificity  in the detection  of  ovarian 
cancer and  discrimination  between  benign  and  ma-
lignant  cases  compared  with CA1259-10.
To date, there are no studies that have examined the 
sensitivity and specificity of  HE4 in Chinese women 
with benign gynecological disorders compared with 
CA125. In the present study, we compared HE4 levels 
with those of  CA125, demonstrating that HE4 was less 
elevated than CA125 in Chinese women with benign 
gynecologic disorders.
Material and methods
From February 2010 to July 2012, 68 patients were in-
cluded in a prospective study conducted at our institu-
tion. All patients were diagnosed with a pelvic mass and 
were scheduled  for  surgical  intervention.   All  patients 
underwent  imaging  by  pelvic ultrasound. Clinical infor-
mation was retrieved from the patients’ hospital notes. 
All patients  underwent  surgical  removal  of  the ovar-
ian  mass.  Before  the collection  of  biological  samples 
and  surgery,  all  patients  were  required  to  give  fully 
informed consent. The protocol was approved by the 
Local Ethics Committee. The Local Ethics Committee 
approved  an analysis  that utilized serum  biomarker 
levels of  HE4 and CA125 as well as serums obtained 
from patients prior to surgery for pelvic mass.
All serum samples were obtained from women prior to 
surgery for pelvic mass. Blood samples were collected 
and centrifuged at 800 g for 10 min. Serum was col-
lected and frozen at -800c. HE4 levels were compared 
with those of  CA125 measured  in the same  samples. 
Serum  HE4  levels  were  determined  using  the  HE4 
EIA  assay (Fujirebio Diagnostics, Göteborg, Swe-
den), and serum CA125 levels were measured using the 
CanAg CA125 EIA assay (Fujirebio Diagnostics, Göte-
borg, Sweden). For CA125, the normal upper limit was 
35 U/mL, whereas that for HE4 was 114 pM. A cut off  
point that provided the best accuracy in the study was 
also determined. We also determined our own ideal cut 
off, corresponding to the highest accuracy.
Pathology   reports   were   reviewed   at   the   time   of  
each   study   and   used   for histopathological classifi-
cation of  the benign neoplasms. Patients were stratified 
by benign   disease   classification.  Percentages   of    el-
evated   biomarker   levels   were determined. The P val-
ues for comparison of  the proportion of  patients with 
elevations in HE4 versus CA125 in the various benign 
histopathological  classifications  were determined.
Result
We assessed the serum HE4 and CA125 levels in 68 chi-
nese women diagnosed benign gynecologic disorders. 
Histopathological results were categorized into 9 sub-
groups.  The cysts subgroup included germinal epithelial 
inclusion, corpus luteal and simple cysts. The subgroup 
of  benign other comprised normal ovaries with other 
benign  gynecological  findings  such  as mesosalpinx 
cyst.  The  subgroup  of   benign undefined indicated 
tumor cannot define because left and right of  ovary 
suffered from two different tumors. Cystadenoma was 
a singe group including both serous and mucinous his-
tology. Hydrosalpinx,  pelvic tuberculosis and abscess 
as well as pelvic inflammatory   disease  were  sorted  to-
gether.  Sex  cord  stromal  tumors  gathered nonspecific 
steroid and Sertoli-Leydig cell tumor. Other subgroups 
encompassed endometriosis and endometriomas, germ 
cell tumors (mature teratoma) and fibroid.The  serum 
HE4  levels  for  all  the  68  cases  divided  by  benign 
pathological categories were shown in Figure1.
Fig.1 Scatter plot of  serum HE4 levels by histopathological classification
 *Median and 95% percentile were shown in figure1. 
The mean, median, SD and range for HE4 and CA125 grouped   by  benign   hispathological   categories   were 
shown   in  Table1. 
Table 1: Analysis of  HE4 and CA125 levels by pathological groups
914                                   915




































Germ cell tumors (mature 
teratoma) 
19 51.2 50.4 30.5-82.6 17.9 16.6 4.5-52.9 
Sex cord stromal tumors 2 54.2 54.2 49.7-58.7 18.7 18.7 13.9-23.5 
Cystadenoma 13 53.0 48.8 31.9-93.0 39.6 17.4 7.3-226.0 
Endometriosis/endometriomas 17 47.1 41.5 29.2-77.2 68.3 35.3 12.7-200.3 
Benign, Undefined 3 56.8 59.6 47.6-63.3 20.5 21.4 17.4-22.8 
Abscess/hydrosalpinx/PID 6 69.9 60.9 50.1-100.2 140.5 40.6 10.4-429.1 
Fibroid 2 96.9 96.9 64.4-129.3 112.2 112.2 55.9-168.5 
Benign, Others(normal ovaries) 3 64.2 71.4 48.5-72.7 23.6 16.6 12.2-41.9 
All benign tumors 68 54.1 50.4 29.2-129.3 49.3 22.1 4.5-429.1 
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Comparison of  serum HE4 and CA125 levels for all 
the cases exhibited in Table2.
Elevation of  HE4 and CA125 levels was determined by 
t-test and 95th percentile cutpoint of  114pM for HE4 
and 35U/mL for CA125 were considered  in statisti-
cal analysis. In 68 chinese women, elevation of  serum 
HE4 levels were less than that of  CA125. HE4 was 
found to be elevated in only 1% (1/68) of  benign cases 
compared with serum CA125 levels that were elevated 
in 29% (20/68) of  cases (P<0.001). Evidence    from 
subgroup    classification    of     benign    gynecological 
disorders demonstrated  that there was a significantly 
difference  in the proportion  of  chinese patients 
where CA125 was elevated compared with HE4 with 
the exception of  fibroid. The  most  significantly   dis-
crepancy   occurred   in   endometriosis/endometrio-
mas subgroup,  in which HE4 was not elevated in 17 
cases and CA125 was elevated in 53%  (9/17)  of   the 
cases  (P<0.001).  Astonishingly,  serum  HE4  levels 
in  chinese women  with  cystadenoma  were  not  el-
evated  in  13  cases  compared  with  CA125, which 
was elevated in 23% (3/13) of  the cases. Appealingly, 
compared with CA125 in germ cell tumors, which was 
elevated in 1 cases (1/19), HE4 levels in serum is less 
elevated (P<0.001). Also, HE4 was significantly less el-
evated compare with CA125 in patients with Ovarian 
cysts (0% V.S. 33%, P=0.002). HE4 was equally found 
to be less  elevated  in  patients  with  inflammatory  dis-
ease  (abscess,  hydrosalpinx,  and PID)(0% V.S. 50%, 
P=0.046). Table 2.






























Germ cell tumors (mature teratoma) 19 0 0  1 5 0.000 
Sex cord stromal tumors 2 0 0  0 0 0.020 
Cystadenoma 13 0 0  3 23 0.000 
Endometriosis/endometriomas 17 0 0  9 53 0.000 
Benign, Undefined 3 0 0  0 0 0.008 
Abscess/hydrosalpinx/PID 6 0 0  3 50 0.046 
Fibroid 2 1 50  2 100 0.437 
Benign, Others(normal ovaries) 3 0 0  1 33 0.042 
All benign tumors 68 1 1  20 29 0.000 
Discussion
HE4 gene was initially identified  in epithelial  cells of  
human epididymis  and was expressed  in  some  normal 
tissues11-12.  Recently,  HE4  was  regarded  as  a  new bi-
omarker,  highly  expressed  in the early stage of  ovarian 
cancer.  However,  serum HE4 levels rarely increased 
in benign gynecologic conditions, suggesting its com-
plementary role to CA12513-15. Similar to CA125, HE4 
levels were significantly higher in patients with ovarian 
cancer compared with levels observed in patients with 
benign disease or healthy controls16.
Several studies have suggested the combing a serum 
HE4 assay with a CA125 assay could   warrant   the 
detection   of    gynecologic   diseases17-19.   HE4   assay 
could complement  the  classical  CA125  assay  to im-
prove  the  detection  of   patients  with ovarian  cancer. 
Moore  et  al.  reported  HE4  levels  in  women  with 
endometriosis increased  in  3%  cases,  compared  with 
CA125,  which  elevated  in  67%  cases13.
Another study showed high HE4 levels in benign and 
gynecologic diseases20. So far, very little was known 
about the HE4 levels in benign gynecological tumors 
and disorders.
Endometriosis was a common gynecologic disorder 
and causes the elevation of  serum CA125. Due to high 
expression of  CA125 in women with endometriosis, it 
lacked of  specificity. Anastasi et al. demonstrated HE4 
never increased in 57 women with endometriosis, with a 
median serum level of  53pM and a range of  26-98pM. 
On the contrary,  CA125 was elevated in 56.1% (32/57) 
of  cases21. In our study, none of  patients with endome-
triosis had elevated serum HE4 levels compare with 
53% (9/17) of  women with elevated serum CA125 lev-
els. Our founding provides strong evidence the specifi-
city of  HE4 over CA125 and the most useful marker 
for diagnosis of  endometriosis from benign and malig-
nant ovarian mass.
Inflammatory situations such as pelvic inflammatory 
disease were known to induce high concentrations of  
CA12522. A raised CA125 levels combined with the 
presence of   pelvic  mass  suggested  an  ovarian  malig-
nancy23.  We  discovered  CA125  was elevated in 50% 
patients, which is consistent those reported by Dong 
et al24, While few patients showed the elevation of  
HE4.
Several  studies  have  shown  CA125  levels  were  in-
creased  in the  patients  with  an ovarian  neoplasm25-26. 
In  this  study,  23%  patients  had elevated  CA125  lev-
els  in contrast to none of  patients with elevated levels 
of  HE4. The most common benign neoplasms were 
serous and mucinous cystadenomas, which accounted 
for 28.4% of  women with benign disease27.
Generally, few patients with benign gynecologic dis-
eases had an elevated HE4 levels compared with that 
with an elevated CA125 levels27-28. This study showed 
Germ cell tumors (mature teratoma) displayed a smaller 
fractions of  cases with elevated HE4 levels compared 
with CA125. However, some benign conditions could 
be associated with high HE4  levels.  Recent  study  had 
reported  high  HE4  levels  in  uterine fibroma30.Con-
sistent with this result, in fibroid subgroup, there was 
no significant difference in the proportion of  women, 
in which both biomarkers were elevated.
Serum HE4, isolated from patients with benign ovar-
ian tumors, had the highest sensitivity as a biomarker, 
which was 67%, with a specificity of  96%29. The com-
bination of  HE4 and CA125 increases the sensitivity 
of  one biomarker alone. In some  cases,  HE4  had 
advantages  over  CA125  in diagnose.  An increased 
of  HE4 levels before CA125 increment were strictly as-
sociated to a relapse of  the disease30. In  addition,  the 
concentrations  of   serum  HE4  was  not  influence  by 
the  phase  of  menstrual cycle and hormonal therapy, 
suggesting a potential role in clinic31-32.
By histopathological  classification,  we  collected  lim-
ited  samples  of   patients  with benign ovarian tumor 
in our study. As a result of  this, elevation of  HE4 or 
CA125 was obvious  in some  histological  types,  such as 
endometriosis/endometriomas, cystadenoma and germ 
cell tumors, while was not significant in other types, 
including patients with inflammatory disease (abscess, 
hydrosalpinx, and PID). Kobel et al. had investigated 
the  expression  pattern  of   21 different  biomarkers 
including  HE4  and CA125 in accordance with his-
pathological classification and reported that biomarker 
expression varies between histological types33.
Overall,  our  data  confirmed  previous  report  that 
HE4  levels  were  not  frequent elevated  in patients 
with  benign  conditions  when  the proportions  of  
patients  with elevated levels of  HE4 and CA125 were 
compared.  This result supported HE4 can provide a 
more accurate tool for diagnosis of  patients with be-
nign ovarian tumors. Future studies will be performed 
to evaluate HE4 levels in a larger of  samples of  sera pa-
tients  with benign  disease  in ovarian  cancer screening 
trails.  At the same  time, healthy controls should be 
included as possible to enhance reliability of  our re-
sults.
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